Results
1
Companies which are more than 50% undervalued based on analyst price target.
1 companies
Lytix Biopharma
Market Cap: NOK 596.7m
A clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.
LYTIX
NOK 7.78
7D
-3.7%
1Y
-16.5%